If you're seeing this message, that means
JavaScript has been disabled on your browser
, please
enable JS
to make this app work.
No tags found
Companies
No companies found
Advanced Search
Newsfeed
Alerts
Saved Lists
Sign Up for Free
Login
Update this Profile
Get Updates
31
Followers on Owler
AnTolRx
develops and commercializes antigen-specific tolerogenic molecules to treat autoimmune diseases..
Read more
Overview
Competitors
Funding
News & Insights
AnTolRx
develops and commercializes antigen-specific tolerogenic molecules to treat autoimmune diseases..
Read more
Chairman & CEO
Mark Carthy
CEO Approval Rating
90/100
Weigh In
2014
Cambridge
Massachusetts
Greater Boston
Private
Pharmaceuticals & Biotechnology
Pharmaceuticals
2836
NAICS listing
https://antolrx.com/
Est. Annual Revenue
$5.0-25M
Agree?
Yes
No
Est. Employees
25-100
Agree?
Yes
No
Funding
$5M
News
Latest News
Mar 07, 2019
in-PharmaTechnologist
AnTolRx: Pfizer licenses immune tolerance therapy for type 1 diabetes
Mar 06, 2019
pipelinereview
AnTolRx: AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes
Follow and Get Alerts
AnTolRx Competitors
1
Follow
2
Follow
3
Follow
4
Follow
5
Follow
6
Follow
7
Follow
8
Follow
9
Follow
10
Follow
Unlock 7 + competitors
Trending Companies
